VEGF-targeted therapy in renal cell carcinoma: Active drugs and active choices

Current Oncology Reports

Volumn 8, Issue 2, 2006, Pages 85-89

  Rini, Brian I ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AG 013736; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; ERLOTINIB; IMIDAZOLE DERIVATIVE; NEXAVAR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ASTHENIA; CANCER CHEMOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DRUG ACTIVITY; DRUG POTENTIATION; DRUG USE; FATIGUE; GENE INACTIVATION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; METASTASIS; MOLECULAR DYNAMICS; NAUSEA; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; STOMATITIS; VON HIPPEL LINDAU DISEASE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PLATELET-DERIVED GROWTH FACTOR; PYRIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33645535119     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0041-5     Document Type: Review

References (37)

1. Bukowski RM: Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001, 19:148-154.
2. Gnarra JR, Tory K, Weng Y, et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85-90.
3. Shuin T, Kondo K, Torigoe S, et al.: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994, 54:2852-2855.
4. Herman JG, Latif F, Weng Y, et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994, 91:9700-9704.
5. Gnarra JR, Lerman MI, Zbar B, Linehan WM: Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 1995, 22:3-8.
6. Hansen WJ, Ohh M, Moslehi J, et al.: Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol Cell Biol 2002, 22:1947-1960.
7. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
8. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
9. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
10. Benjamin LE, Golijanin D, Itin A, et al.: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159-165.
11. Jain RK, Safabakhsh N, Sckell A, et al.: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998, 95:10820-10825.
12. Watanabe Y, Lee SW, Detmar M, et al.: Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 1997, 14:2025-2032.
13. Heldin CH, Ostman A, Ronnstrand L: Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998, 1378:F79-F113.
14. Knebelmann B, Ananth S, Cohen HT, Sukhatme VP: Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998, 58:226-231.
15. de Paulsen N, Brychzy A, Fournier MC, et al.: Role of transforming growth factor-alpha in von Hippel-Lindau (VHL) (-/-) clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 2001, 98:1387-1392.
16. Gunaratnam L, Morley M, Franovic A, et al.: Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 2003, 278:44966-44974.
17. Presta LG, Chen H, O'Connor SJ, et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
18. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 2003, 349:427-434.
19. Yang JC: Bevacizumab for patients with metastatic renal cancer: An update. Clin Cancer Res 2004, 10:6367S-6370S.
20. Rini BI, Halabi S, Taylor J, et al.: Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004, 10:2584-2586.
21. Sun L, Liang C, Shirazian S, et al.: Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003, 46:1116-1119.
22. Mendel DB, Laird AD, Xin X, et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
23. Motzer RJ, Rini BI, Michaelson MD, et al.: Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc ASCO 2005, 23(16S):4508.
24. Lyons JF, Wilhelm S, Hibner B, Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer, 2001, 8:219-225.
25. Wilhelm SM, Carter C, Tang L, et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64:7099-7109.
26. Ratain MJ, Eisen T, Stadler WM, et al.: Final findings from a Phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract]. Proc ASCO 2005, 23(16S):4544.
27. Escudier B, Szczylik C, Eisen T, et al.: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract]. Proc ASCO 2005, 23(16S):4510.
28. Inai T, Mancuso M, Hashizume H, et al.: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165:35-52.
29. Rini B, Rixe O, Bukowski R, et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC) [abstract]. Proc ASCO 2005, 23(16S):4509.
30. Motzer RJ, Amato R, Todd M, et al.: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003, 21:99-101.
31. Drucker B, Bacik J, Ginsberg M, et al.: Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003, 21:341-345.
32. Dawson NA, Guo C, Zak R, et al.: A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 2004, 10:7812-7819.
33. Viloria-Petit A, Crombet T, Jothy S, et al.: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res, 2001, 61:5090-5101.
34. Spigel DR, Hainsworth JD, Sosman JA, et al.: Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial [abstract]. Proc ASCO 2005, 23 (16S):4540.
35. Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet 1999, 353:14-17.
36. Fyfe GA, Fisher RI, Rosenberg SA, et al.: Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996, 14:2410-2411.
37. Pyrhonen S, Salminen E, Ruutu M, et al.: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol, 1999, 17:2859-2867.